249 related articles for article (PubMed ID: 26148673)
1. Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.
Sung TY; Kim M; Kim TY; Kim WG; Park Y; Song DE; Park SY; Kwon H; Choi YM; Jang EK; Jeon MJ; Shong YK; Hong SJ; Kim WB
Thyroid; 2015 Sep; 25(9):1020-5. PubMed ID: 26148673
[TBL] [Abstract][Full Text] [Related]
2. Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.
Nilubol N; Boufraqech M; Zhang L; Kebebew E
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1173-82. PubMed ID: 24654752
[TBL] [Abstract][Full Text] [Related]
3. Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population.
Yim JH; Kim WG; Jeon MJ; Han JM; Kim TY; Yoon JH; Hong SJ; Song DE; Gong G; Shong YK; Kim WB
Thyroid; 2014 Apr; 24(4):689-94. PubMed ID: 24124924
[TBL] [Abstract][Full Text] [Related]
4. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
[TBL] [Abstract][Full Text] [Related]
5. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
[TBL] [Abstract][Full Text] [Related]
7. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
8. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
9. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer.
Ivković I; Limani Z; Jakovčević A; Gajović S; Seiwerth S; Đanić Hadžibegović A; Prgomet D
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672561
[TBL] [Abstract][Full Text] [Related]
11. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
[TBL] [Abstract][Full Text] [Related]
12. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
[TBL] [Abstract][Full Text] [Related]
13. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
14. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.
Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L
Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
17. Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma.
Pyo JS; Kang G; Kim DH; Chae SW; Park C; Kim K; Do SI; Lee HJ; Kim JH; Sohn JH
Pathol Res Pract; 2013 Apr; 209(4):228-32. PubMed ID: 23528368
[TBL] [Abstract][Full Text] [Related]
18. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
19. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
20. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
